nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—P-Glycoprotein Inhibitors—Lopinavir—acquired immunodeficiency syndrome	0.314	0.623	CiPCiCtD
Vemurafenib—P-Glycoprotein Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.19	0.377	CiPCiCtD
Vemurafenib—ALB—acquired immunodeficiency syndrome	0.115	1	CbGaD
Vemurafenib—ABCC1—Amprenavir—acquired immunodeficiency syndrome	0.0227	0.0778	CbGbCtD
Vemurafenib—ABCC1—Indinavir—acquired immunodeficiency syndrome	0.0196	0.0672	CbGbCtD
Vemurafenib—ORM1—Saquinavir—acquired immunodeficiency syndrome	0.0188	0.0647	CbGbCtD
Vemurafenib—ABCC1—Ritonavir—acquired immunodeficiency syndrome	0.0172	0.059	CbGbCtD
Vemurafenib—ABCC1—Saquinavir—acquired immunodeficiency syndrome	0.0172	0.059	CbGbCtD
Vemurafenib—ABCC1—Lamivudine—acquired immunodeficiency syndrome	0.0127	0.0437	CbGbCtD
Vemurafenib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0127	0.0436	CbGbCtD
Vemurafenib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0115	0.0395	CbGbCtD
Vemurafenib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0115	0.0395	CbGbCtD
Vemurafenib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.011	0.0378	CbGbCtD
Vemurafenib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00853	0.0293	CbGbCtD
Vemurafenib—ALB—Saquinavir—acquired immunodeficiency syndrome	0.00793	0.0272	CbGbCtD
Vemurafenib—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0076	0.0261	CbGbCtD
Vemurafenib—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.00736	0.0253	CbGbCtD
Vemurafenib—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.00692	0.0237	CbGbCtD
Vemurafenib—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.00692	0.0237	CbGbCtD
Vemurafenib—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.00626	0.0215	CbGbCtD
Vemurafenib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00606	0.0208	CbGbCtD
Vemurafenib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0057	0.0196	CbGbCtD
Vemurafenib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0057	0.0196	CbGbCtD
Vemurafenib—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00524	0.018	CbGbCtD
Vemurafenib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00516	0.0177	CbGbCtD
Vemurafenib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00516	0.0177	CbGbCtD
Vemurafenib—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00474	0.0163	CbGbCtD
Vemurafenib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00445	0.0153	CbGbCtD
Vemurafenib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00432	0.0148	CbGbCtD
Vemurafenib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00391	0.0134	CbGbCtD
Vemurafenib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00391	0.0134	CbGbCtD
Vemurafenib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00386	0.0132	CbGbCtD
Vemurafenib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00363	0.0124	CbGbCtD
Vemurafenib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00363	0.0124	CbGbCtD
Vemurafenib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00328	0.0112	CbGbCtD
Vemurafenib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00328	0.0112	CbGbCtD
Vemurafenib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00283	0.00971	CbGbCtD
Vemurafenib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00275	0.00943	CbGbCtD
Vemurafenib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00248	0.00853	CbGbCtD
Vemurafenib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00248	0.00853	CbGbCtD
Vemurafenib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00238	0.00817	CbGbCtD
Vemurafenib—ORM1—saliva—acquired immunodeficiency syndrome	0.00185	0.113	CbGeAlD
Vemurafenib—BRAF—blood—acquired immunodeficiency syndrome	0.000641	0.0393	CbGeAlD
Vemurafenib—BRAF—bone marrow—acquired immunodeficiency syndrome	0.00062	0.038	CbGeAlD
Vemurafenib—BRAF—vagina—acquired immunodeficiency syndrome	0.000594	0.0364	CbGeAlD
Vemurafenib—BRAF—lung—acquired immunodeficiency syndrome	0.000562	0.0344	CbGeAlD
Vemurafenib—RAF1—skin of body—acquired immunodeficiency syndrome	0.00056	0.0343	CbGeAlD
Vemurafenib—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000464	0.0284	CbGeAlD
Vemurafenib—RAF1—lymphoid tissue—acquired immunodeficiency syndrome	0.000454	0.0278	CbGeAlD
Vemurafenib—RAF1—digestive system—acquired immunodeficiency syndrome	0.000448	0.0275	CbGeAlD
Vemurafenib—RAF1—blood—acquired immunodeficiency syndrome	0.000427	0.0262	CbGeAlD
Vemurafenib—RAF1—bone marrow—acquired immunodeficiency syndrome	0.000413	0.0253	CbGeAlD
Vemurafenib—RAF1—spinal cord—acquired immunodeficiency syndrome	0.000411	0.0252	CbGeAlD
Vemurafenib—BRAF—brain—acquired immunodeficiency syndrome	0.000398	0.0244	CbGeAlD
Vemurafenib—RAF1—vagina—acquired immunodeficiency syndrome	0.000396	0.0243	CbGeAlD
Vemurafenib—BRAF—lymph node—acquired immunodeficiency syndrome	0.000384	0.0235	CbGeAlD
Vemurafenib—RAF1—lung—acquired immunodeficiency syndrome	0.000374	0.0229	CbGeAlD
Vemurafenib—RAF1—nervous system—acquired immunodeficiency syndrome	0.000347	0.0212	CbGeAlD
Vemurafenib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000336	0.0206	CbGeAlD
Vemurafenib—RAF1—central nervous system—acquired immunodeficiency syndrome	0.000334	0.0204	CbGeAlD
Vemurafenib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000331	0.0203	CbGeAlD
Vemurafenib—ORM1—blood—acquired immunodeficiency syndrome	0.000295	0.0181	CbGeAlD
Vemurafenib—ORM1—bone marrow—acquired immunodeficiency syndrome	0.000285	0.0175	CbGeAlD
Vemurafenib—ORM1—spinal cord—acquired immunodeficiency syndrome	0.000284	0.0174	CbGeAlD
Vemurafenib—RAF1—brain—acquired immunodeficiency syndrome	0.000265	0.0162	CbGeAlD
Vemurafenib—ORM1—lung—acquired immunodeficiency syndrome	0.000258	0.0158	CbGeAlD
Vemurafenib—RAF1—lymph node—acquired immunodeficiency syndrome	0.000256	0.0157	CbGeAlD
Vemurafenib—ORM1—nervous system—acquired immunodeficiency syndrome	0.000239	0.0147	CbGeAlD
Vemurafenib—ORM1—central nervous system—acquired immunodeficiency syndrome	0.00023	0.0141	CbGeAlD
Vemurafenib—ABCC1—blood—acquired immunodeficiency syndrome	0.000213	0.0131	CbGeAlD
Vemurafenib—ABCC1—vagina—acquired immunodeficiency syndrome	0.000198	0.0121	CbGeAlD
Vemurafenib—ABCC1—lung—acquired immunodeficiency syndrome	0.000187	0.0115	CbGeAlD
Vemurafenib—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000178	0.0109	CbGeAlD
Vemurafenib—ORM1—lymph node—acquired immunodeficiency syndrome	0.000177	0.0108	CbGeAlD
Vemurafenib—ABCG2—blood—acquired immunodeficiency syndrome	0.000177	0.0108	CbGeAlD
Vemurafenib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000171	0.0105	CbGeAlD
Vemurafenib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.00017	0.0104	CbGeAlD
Vemurafenib—CYP1A2—blood—acquired immunodeficiency syndrome	0.00017	0.0104	CbGeAlD
Vemurafenib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000164	0.01	CbGeAlD
Vemurafenib—ALB—brain—acquired immunodeficiency syndrome	0.00016	0.00983	CbGeAlD
Vemurafenib—ALB—lymph node—acquired immunodeficiency syndrome	0.000155	0.0095	CbGeAlD
Vemurafenib—ABCG2—lung—acquired immunodeficiency syndrome	0.000155	0.00949	CbGeAlD
Vemurafenib—CYP1A2—lung—acquired immunodeficiency syndrome	0.000149	0.00913	CbGeAlD
Vemurafenib—ABCC1—brain—acquired immunodeficiency syndrome	0.000132	0.00811	CbGeAlD
Vemurafenib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000129	0.00791	CbGeAlD
Vemurafenib—ABCC1—lymph node—acquired immunodeficiency syndrome	0.000128	0.00784	CbGeAlD
Vemurafenib—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000127	0.00779	CbGeAlD
Vemurafenib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000123	0.00754	CbGeAlD
Vemurafenib—CYP2D6—blood—acquired immunodeficiency syndrome	0.000121	0.00742	CbGeAlD
Vemurafenib—ABCG2—brain—acquired immunodeficiency syndrome	0.00011	0.00672	CbGeAlD
Vemurafenib—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000106	0.00649	CbGeAlD
Vemurafenib—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000104	0.00154	CcSEcCtD
Vemurafenib—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.00154	CcSEcCtD
Vemurafenib—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.00154	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000104	0.00154	CcSEcCtD
Vemurafenib—Erythema multiforme—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.00154	CcSEcCtD
Vemurafenib—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000104	0.00154	CcSEcCtD
Vemurafenib—Cough—Indinavir—acquired immunodeficiency syndrome	0.000104	0.00153	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000104	0.00153	CcSEcCtD
Vemurafenib—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.00153	CcSEcCtD
Vemurafenib—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000104	0.00153	CcSEcCtD
Vemurafenib—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.00152	CcSEcCtD
Vemurafenib—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.00152	CcSEcCtD
Vemurafenib—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000103	0.00152	CcSEcCtD
Vemurafenib—Eye disorder—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.00152	CcSEcCtD
Vemurafenib—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000103	0.00152	CcSEcCtD
Vemurafenib—Chills—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.00152	CcSEcCtD
Vemurafenib—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000102	0.00151	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000102	0.00151	CcSEcCtD
Vemurafenib—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.00151	CcSEcCtD
Vemurafenib—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000102	0.00151	CcSEcCtD
Vemurafenib—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000102	0.00151	CcSEcCtD
Vemurafenib—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000101	0.0015	CcSEcCtD
Vemurafenib—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.000101	0.0015	CcSEcCtD
Vemurafenib—Myalgia—Indinavir—acquired immunodeficiency syndrome	0.000101	0.0015	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000101	0.00149	CcSEcCtD
Vemurafenib—CYP3A4—nervous system—acquired immunodeficiency syndrome	9.99e-05	0.00612	CbGeAlD
Vemurafenib—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	9.97e-05	0.00147	CcSEcCtD
Vemurafenib—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	9.94e-05	0.00147	CcSEcCtD
Vemurafenib—Asthenia—Didanosine—acquired immunodeficiency syndrome	9.92e-05	0.00147	CcSEcCtD
Vemurafenib—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	9.92e-05	0.00147	CcSEcCtD
Vemurafenib—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	9.91e-05	0.00146	CcSEcCtD
Vemurafenib—Chills—Saquinavir—acquired immunodeficiency syndrome	9.86e-05	0.00146	CcSEcCtD
Vemurafenib—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	9.83e-05	0.00145	CcSEcCtD
Vemurafenib—CYP2D6—nervous system—acquired immunodeficiency syndrome	9.83e-05	0.00602	CbGeAlD
Vemurafenib—Cough—Efavirenz—acquired immunodeficiency syndrome	9.81e-05	0.00145	CcSEcCtD
Vemurafenib—Pruritus—Didanosine—acquired immunodeficiency syndrome	9.79e-05	0.00145	CcSEcCtD
Vemurafenib—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	9.74e-05	0.00144	CcSEcCtD
Vemurafenib—Alopecia—Saquinavir—acquired immunodeficiency syndrome	9.71e-05	0.00144	CcSEcCtD
Vemurafenib—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	9.71e-05	0.00144	CcSEcCtD
Vemurafenib—Vomiting—Amprenavir—acquired immunodeficiency syndrome	9.65e-05	0.00143	CcSEcCtD
Vemurafenib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	9.62e-05	0.00589	CbGeAlD
Vemurafenib—Back pain—Ritonavir—acquired immunodeficiency syndrome	9.62e-05	0.00142	CcSEcCtD
Vemurafenib—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	9.57e-05	0.00142	CcSEcCtD
Vemurafenib—Erythema—Saquinavir—acquired immunodeficiency syndrome	9.57e-05	0.00142	CcSEcCtD
Vemurafenib—Myalgia—Efavirenz—acquired immunodeficiency syndrome	9.57e-05	0.00141	CcSEcCtD
Vemurafenib—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	9.57e-05	0.00141	CcSEcCtD
Vemurafenib—Rash—Amprenavir—acquired immunodeficiency syndrome	9.57e-05	0.00141	CcSEcCtD
Vemurafenib—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	9.56e-05	0.00141	CcSEcCtD
Vemurafenib—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	9.52e-05	0.00141	CcSEcCtD
Vemurafenib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	9.52e-05	0.00141	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	9.51e-05	0.00141	CcSEcCtD
Vemurafenib—Headache—Amprenavir—acquired immunodeficiency syndrome	9.51e-05	0.00141	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	9.5e-05	0.0014	CcSEcCtD
Vemurafenib—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	9.49e-05	0.0014	CcSEcCtD
Vemurafenib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	9.46e-05	0.0058	CbGeAlD
Vemurafenib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	9.46e-05	0.0014	CcSEcCtD
Vemurafenib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	9.45e-05	0.0014	CcSEcCtD
Vemurafenib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	9.43e-05	0.00139	CcSEcCtD
Vemurafenib—Chills—Lamivudine—acquired immunodeficiency syndrome	9.41e-05	0.00139	CcSEcCtD
Vemurafenib—Cough—Delavirdine—acquired immunodeficiency syndrome	9.38e-05	0.00139	CcSEcCtD
Vemurafenib—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	9.37e-05	0.00139	CcSEcCtD
Vemurafenib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	9.35e-05	0.00138	CcSEcCtD
Vemurafenib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	9.27e-05	0.00137	CcSEcCtD
Vemurafenib—Back pain—Saquinavir—acquired immunodeficiency syndrome	9.26e-05	0.00137	CcSEcCtD
Vemurafenib—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	9.16e-05	0.00135	CcSEcCtD
Vemurafenib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	9.15e-05	0.00135	CcSEcCtD
Vemurafenib—Myalgia—Delavirdine—acquired immunodeficiency syndrome	9.15e-05	0.00135	CcSEcCtD
Vemurafenib—Erythema—Lamivudine—acquired immunodeficiency syndrome	9.13e-05	0.00135	CcSEcCtD
Vemurafenib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	9.13e-05	0.00135	CcSEcCtD
Vemurafenib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	9.07e-05	0.00134	CcSEcCtD
Vemurafenib—Nausea—Amprenavir—acquired immunodeficiency syndrome	9.01e-05	0.00133	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	9.01e-05	0.00133	CcSEcCtD
Vemurafenib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	9e-05	0.00133	CcSEcCtD
Vemurafenib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	8.99e-05	0.00133	CcSEcCtD
Vemurafenib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	8.94e-05	0.00132	CcSEcCtD
Vemurafenib—Constipation—Zidovudine—acquired immunodeficiency syndrome	8.93e-05	0.00132	CcSEcCtD
Vemurafenib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	8.92e-05	0.00132	CcSEcCtD
Vemurafenib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	8.91e-05	0.00132	CcSEcCtD
Vemurafenib—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	8.87e-05	0.00131	CcSEcCtD
Vemurafenib—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	8.85e-05	0.00131	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	8.84e-05	0.00131	CcSEcCtD
Vemurafenib—Back pain—Lamivudine—acquired immunodeficiency syndrome	8.83e-05	0.00131	CcSEcCtD
Vemurafenib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	8.8e-05	0.0013	CcSEcCtD
Vemurafenib—Vomiting—Didanosine—acquired immunodeficiency syndrome	8.79e-05	0.0013	CcSEcCtD
Vemurafenib—Rash—Didanosine—acquired immunodeficiency syndrome	8.72e-05	0.00129	CcSEcCtD
Vemurafenib—Infection—Delavirdine—acquired immunodeficiency syndrome	8.72e-05	0.00129	CcSEcCtD
Vemurafenib—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	8.72e-05	0.00129	CcSEcCtD
Vemurafenib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	8.71e-05	0.00129	CcSEcCtD
Vemurafenib—Cough—Ritonavir—acquired immunodeficiency syndrome	8.68e-05	0.00128	CcSEcCtD
Vemurafenib—Headache—Didanosine—acquired immunodeficiency syndrome	8.67e-05	0.00128	CcSEcCtD
Vemurafenib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	8.64e-05	0.00128	CcSEcCtD
Vemurafenib—Asthenia—Stavudine—acquired immunodeficiency syndrome	8.62e-05	0.00127	CcSEcCtD
Vemurafenib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	8.52e-05	0.00126	CcSEcCtD
Vemurafenib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	8.52e-05	0.00126	CcSEcCtD
Vemurafenib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	8.51e-05	0.00126	CcSEcCtD
Vemurafenib—Pruritus—Stavudine—acquired immunodeficiency syndrome	8.5e-05	0.00126	CcSEcCtD
Vemurafenib—Asthenia—Abacavir—acquired immunodeficiency syndrome	8.49e-05	0.00126	CcSEcCtD
Vemurafenib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	8.46e-05	0.00125	CcSEcCtD
Vemurafenib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	8.46e-05	0.00125	CcSEcCtD
Vemurafenib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	8.44e-05	0.00125	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	8.41e-05	0.00124	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	8.38e-05	0.00124	CcSEcCtD
Vemurafenib—Pruritus—Abacavir—acquired immunodeficiency syndrome	8.37e-05	0.00124	CcSEcCtD
Vemurafenib—Fatigue—Indinavir—acquired immunodeficiency syndrome	8.37e-05	0.00124	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	8.36e-05	0.00124	CcSEcCtD
Vemurafenib—Cough—Saquinavir—acquired immunodeficiency syndrome	8.35e-05	0.00123	CcSEcCtD
Vemurafenib—Constipation—Indinavir—acquired immunodeficiency syndrome	8.3e-05	0.00123	CcSEcCtD
Vemurafenib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.25e-05	0.00122	CcSEcCtD
Vemurafenib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.24e-05	0.00122	CcSEcCtD
Vemurafenib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.22e-05	0.00121	CcSEcCtD
Vemurafenib—Nausea—Didanosine—acquired immunodeficiency syndrome	8.22e-05	0.00121	CcSEcCtD
Vemurafenib—Hypotension—Delavirdine—acquired immunodeficiency syndrome	8.2e-05	0.00121	CcSEcCtD
Vemurafenib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	8.15e-05	0.0012	CcSEcCtD
Vemurafenib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.15e-05	0.0012	CcSEcCtD
Vemurafenib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.09e-05	0.0012	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	8.09e-05	0.0012	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	7.99e-05	0.00118	CcSEcCtD
Vemurafenib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	7.97e-05	0.00118	CcSEcCtD
Vemurafenib—Cough—Lamivudine—acquired immunodeficiency syndrome	7.97e-05	0.00118	CcSEcCtD
Vemurafenib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	7.97e-05	0.00118	CcSEcCtD
Vemurafenib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	7.96e-05	0.00118	CcSEcCtD
Vemurafenib—Dizziness—Stavudine—acquired immunodeficiency syndrome	7.94e-05	0.00117	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	7.92e-05	0.00117	CcSEcCtD
Vemurafenib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	7.91e-05	0.00117	CcSEcCtD
Vemurafenib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	7.91e-05	0.00117	CcSEcCtD
Vemurafenib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	7.88e-05	0.00117	CcSEcCtD
Vemurafenib—Constipation—Efavirenz—acquired immunodeficiency syndrome	7.84e-05	0.00116	CcSEcCtD
Vemurafenib—Rash—Nevirapine—acquired immunodeficiency syndrome	7.84e-05	0.00116	CcSEcCtD
Vemurafenib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	7.83e-05	0.00116	CcSEcCtD
Vemurafenib—Dizziness—Abacavir—acquired immunodeficiency syndrome	7.82e-05	0.00116	CcSEcCtD
Vemurafenib—Headache—Nevirapine—acquired immunodeficiency syndrome	7.79e-05	0.00115	CcSEcCtD
Vemurafenib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	7.77e-05	0.00115	CcSEcCtD
Vemurafenib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	7.77e-05	0.00115	CcSEcCtD
Vemurafenib—Infection—Saquinavir—acquired immunodeficiency syndrome	7.76e-05	0.00115	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	7.72e-05	0.00114	CcSEcCtD
Vemurafenib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	7.67e-05	0.00113	CcSEcCtD
Vemurafenib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	7.66e-05	0.00113	CcSEcCtD
Vemurafenib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	7.66e-05	0.00113	CcSEcCtD
Vemurafenib—Vomiting—Stavudine—acquired immunodeficiency syndrome	7.64e-05	0.00113	CcSEcCtD
Vemurafenib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	7.63e-05	0.00113	CcSEcCtD
Vemurafenib—Rash—Nelfinavir—acquired immunodeficiency syndrome	7.59e-05	0.00112	CcSEcCtD
Vemurafenib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	7.59e-05	0.00112	CcSEcCtD
Vemurafenib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	7.59e-05	0.00112	CcSEcCtD
Vemurafenib—Hypotension—Ritonavir—acquired immunodeficiency syndrome	7.58e-05	0.00112	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	7.58e-05	0.00112	CcSEcCtD
Vemurafenib—Rash—Stavudine—acquired immunodeficiency syndrome	7.57e-05	0.00112	CcSEcCtD
Vemurafenib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	7.57e-05	0.00112	CcSEcCtD
Vemurafenib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	7.56e-05	0.00112	CcSEcCtD
Vemurafenib—Headache—Nelfinavir—acquired immunodeficiency syndrome	7.55e-05	0.00112	CcSEcCtD
Vemurafenib—Headache—Stavudine—acquired immunodeficiency syndrome	7.52e-05	0.00111	CcSEcCtD
Vemurafenib—Vomiting—Abacavir—acquired immunodeficiency syndrome	7.52e-05	0.00111	CcSEcCtD
Vemurafenib—CYP2D6—brain—acquired immunodeficiency syndrome	7.51e-05	0.0046	CbGeAlD
Vemurafenib—Constipation—Delavirdine—acquired immunodeficiency syndrome	7.5e-05	0.00111	CcSEcCtD
Vemurafenib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	7.49e-05	0.00111	CcSEcCtD
Vemurafenib—Rash—Abacavir—acquired immunodeficiency syndrome	7.46e-05	0.0011	CcSEcCtD
Vemurafenib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	7.45e-05	0.0011	CcSEcCtD
Vemurafenib—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	7.45e-05	0.0011	CcSEcCtD
Vemurafenib—Headache—Abacavir—acquired immunodeficiency syndrome	7.41e-05	0.0011	CcSEcCtD
Vemurafenib—Infection—Lamivudine—acquired immunodeficiency syndrome	7.4e-05	0.00109	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	7.39e-05	0.00109	CcSEcCtD
Vemurafenib—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.39e-05	0.00109	CcSEcCtD
Vemurafenib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	7.38e-05	0.00109	CcSEcCtD
Vemurafenib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	7.31e-05	0.00108	CcSEcCtD
Vemurafenib—Hypotension—Saquinavir—acquired immunodeficiency syndrome	7.3e-05	0.00108	CcSEcCtD
Vemurafenib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.25e-05	0.00107	CcSEcCtD
Vemurafenib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.24e-05	0.00107	CcSEcCtD
Vemurafenib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.15e-05	0.00106	CcSEcCtD
Vemurafenib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	7.15e-05	0.00106	CcSEcCtD
Vemurafenib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.14e-05	0.00106	CcSEcCtD
Vemurafenib—Nausea—Stavudine—acquired immunodeficiency syndrome	7.13e-05	0.00105	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.12e-05	0.00105	CcSEcCtD
Vemurafenib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.05e-05	0.00104	CcSEcCtD
Vemurafenib—Nausea—Abacavir—acquired immunodeficiency syndrome	7.03e-05	0.00104	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.01e-05	0.00104	CcSEcCtD
Vemurafenib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7e-05	0.00103	CcSEcCtD
Vemurafenib—Asthenia—Indinavir—acquired immunodeficiency syndrome	6.96e-05	0.00103	CcSEcCtD
Vemurafenib—Hypotension—Lamivudine—acquired immunodeficiency syndrome	6.96e-05	0.00103	CcSEcCtD
Vemurafenib—Constipation—Ritonavir—acquired immunodeficiency syndrome	6.94e-05	0.00103	CcSEcCtD
Vemurafenib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	6.94e-05	0.00103	CcSEcCtD
Vemurafenib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	6.9e-05	0.00102	CcSEcCtD
Vemurafenib—Pruritus—Indinavir—acquired immunodeficiency syndrome	6.87e-05	0.00102	CcSEcCtD
Vemurafenib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	6.79e-05	0.001	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	6.79e-05	0.001	CcSEcCtD
Vemurafenib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	6.76e-05	0.000999	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	6.74e-05	0.000997	CcSEcCtD
Vemurafenib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	6.73e-05	0.000996	CcSEcCtD
Vemurafenib—Constipation—Saquinavir—acquired immunodeficiency syndrome	6.68e-05	0.000988	CcSEcCtD
Vemurafenib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	6.64e-05	0.000982	CcSEcCtD
Vemurafenib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	6.64e-05	0.000981	CcSEcCtD
Vemurafenib—Rash—Zidovudine—acquired immunodeficiency syndrome	6.58e-05	0.000973	CcSEcCtD
Vemurafenib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	6.58e-05	0.000973	CcSEcCtD
Vemurafenib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	6.57e-05	0.000972	CcSEcCtD
Vemurafenib—Headache—Zidovudine—acquired immunodeficiency syndrome	6.54e-05	0.000967	CcSEcCtD
Vemurafenib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	6.49e-05	0.000959	CcSEcCtD
Vemurafenib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	6.48e-05	0.000958	CcSEcCtD
Vemurafenib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	6.47e-05	0.000956	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.43e-05	0.000951	CcSEcCtD
Vemurafenib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.42e-05	0.00095	CcSEcCtD
Vemurafenib—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.42e-05	0.000949	CcSEcCtD
Vemurafenib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.41e-05	0.000949	CcSEcCtD
Vemurafenib—Constipation—Lamivudine—acquired immunodeficiency syndrome	6.37e-05	0.000942	CcSEcCtD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IFNA1—acquired immunodeficiency syndrome	6.34e-05	0.0131	CbGpPWpGaD
Vemurafenib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.3e-05	0.000931	CcSEcCtD
Vemurafenib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.27e-05	0.000928	CcSEcCtD
Vemurafenib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	6.21e-05	0.000918	CcSEcCtD
Vemurafenib—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.2e-05	0.000917	CcSEcCtD
Vemurafenib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.17e-05	0.000913	CcSEcCtD
Vemurafenib—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.17e-05	0.000913	CcSEcCtD
Vemurafenib—Rash—Indinavir—acquired immunodeficiency syndrome	6.12e-05	0.000905	CcSEcCtD
Vemurafenib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.11e-05	0.000904	CcSEcCtD
Vemurafenib—Headache—Indinavir—acquired immunodeficiency syndrome	6.08e-05	0.000899	CcSEcCtD
Vemurafenib—RAF1—BCR signaling pathway—CD79A—acquired immunodeficiency syndrome	6.08e-05	0.0126	CbGpPWpGaD
Vemurafenib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.06e-05	0.000897	CcSEcCtD
Vemurafenib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6e-05	0.000888	CcSEcCtD
Vemurafenib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	5.98e-05	0.000884	CcSEcCtD
Vemurafenib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	5.89e-05	0.000871	CcSEcCtD
Vemurafenib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	5.83e-05	0.000862	CcSEcCtD
Vemurafenib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	5.82e-05	0.000861	CcSEcCtD
Vemurafenib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.8e-05	0.000858	CcSEcCtD
Vemurafenib—Rash—Efavirenz—acquired immunodeficiency syndrome	5.78e-05	0.000855	CcSEcCtD
Vemurafenib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	5.78e-05	0.000854	CcSEcCtD
Vemurafenib—ABCG2—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	5.77e-05	0.0119	CbGpPWpGaD
Vemurafenib—ABCG2—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	5.77e-05	0.0119	CbGpPWpGaD
Vemurafenib—Nausea—Indinavir—acquired immunodeficiency syndrome	5.77e-05	0.000853	CcSEcCtD
Vemurafenib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	5.75e-05	0.000851	CcSEcCtD
Vemurafenib—Headache—Efavirenz—acquired immunodeficiency syndrome	5.75e-05	0.00085	CcSEcCtD
Vemurafenib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	5.74e-05	0.000849	CcSEcCtD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—ACTG1—acquired immunodeficiency syndrome	5.69e-05	0.0118	CbGpPWpGaD
Vemurafenib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.6e-05	0.000829	CcSEcCtD
Vemurafenib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.58e-05	0.000825	CcSEcCtD
Vemurafenib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.55e-05	0.000821	CcSEcCtD
Vemurafenib—Rash—Delavirdine—acquired immunodeficiency syndrome	5.53e-05	0.000818	CcSEcCtD
Vemurafenib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.53e-05	0.000817	CcSEcCtD
Vemurafenib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	5.53e-05	0.000817	CcSEcCtD
Vemurafenib—Headache—Delavirdine—acquired immunodeficiency syndrome	5.5e-05	0.000813	CcSEcCtD
Vemurafenib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	5.49e-05	0.000812	CcSEcCtD
Vemurafenib—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.45e-05	0.000805	CcSEcCtD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—CCL3—acquired immunodeficiency syndrome	5.37e-05	0.0111	CbGpPWpGaD
Vemurafenib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.37e-05	0.000793	CcSEcCtD
Vemurafenib—BRAF—Signalling to p38 via RIT and RIN—IL6—acquired immunodeficiency syndrome	5.36e-05	0.0111	CbGpPWpGaD
Vemurafenib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.35e-05	0.00079	CcSEcCtD
Vemurafenib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.34e-05	0.00079	CcSEcCtD
Vemurafenib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	5.27e-05	0.000779	CcSEcCtD
Vemurafenib—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.21e-05	0.000771	CcSEcCtD
Vemurafenib—BRAF—ARMS-mediated activation—IL6—acquired immunodeficiency syndrome	5.17e-05	0.0107	CbGpPWpGaD
Vemurafenib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.16e-05	0.000764	CcSEcCtD
Vemurafenib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.16e-05	0.000763	CcSEcCtD
Vemurafenib—Rash—Ritonavir—acquired immunodeficiency syndrome	5.12e-05	0.000757	CcSEcCtD
Vemurafenib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.11e-05	0.000756	CcSEcCtD
Vemurafenib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.1e-05	0.000754	CcSEcCtD
Vemurafenib—Headache—Ritonavir—acquired immunodeficiency syndrome	5.08e-05	0.000752	CcSEcCtD
Vemurafenib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	4.97e-05	0.000734	CcSEcCtD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—CD8A—acquired immunodeficiency syndrome	4.96e-05	0.0103	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of retinoblastoma protein—CSF2—acquired immunodeficiency syndrome	4.96e-05	0.0103	CbGpPWpGaD
Vemurafenib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	4.93e-05	0.000729	CcSEcCtD
Vemurafenib—Rash—Saquinavir—acquired immunodeficiency syndrome	4.92e-05	0.000728	CcSEcCtD
Vemurafenib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	4.92e-05	0.000727	CcSEcCtD
Vemurafenib—Headache—Saquinavir—acquired immunodeficiency syndrome	4.89e-05	0.000723	CcSEcCtD
Vemurafenib—BRAF—Frs2-mediated activation—IL6—acquired immunodeficiency syndrome	4.84e-05	0.01	CbGpPWpGaD
Vemurafenib—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.82e-05	0.000713	CcSEcCtD
Vemurafenib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.74e-05	0.0007	CcSEcCtD
Vemurafenib—Rash—Lamivudine—acquired immunodeficiency syndrome	4.7e-05	0.000695	CcSEcCtD
Vemurafenib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.69e-05	0.000694	CcSEcCtD
Vemurafenib—RAF1—Focal Adhesion—ACTG1—acquired immunodeficiency syndrome	4.69e-05	0.0097	CbGpPWpGaD
Vemurafenib—Headache—Lamivudine—acquired immunodeficiency syndrome	4.67e-05	0.00069	CcSEcCtD
Vemurafenib—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.64e-05	0.000686	CcSEcCtD
Vemurafenib—RAF1—RAF/MAP kinase cascade—IL6—acquired immunodeficiency syndrome	4.56e-05	0.00943	CbGpPWpGaD
Vemurafenib—BRAF—Prolonged ERK activation events—IL6—acquired immunodeficiency syndrome	4.55e-05	0.00942	CbGpPWpGaD
Vemurafenib—RAF1—B Cell Receptor Signaling Pathway—CD79A—acquired immunodeficiency syndrome	4.52e-05	0.00935	CbGpPWpGaD
Vemurafenib—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.43e-05	0.000654	CcSEcCtD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—IFNG—acquired immunodeficiency syndrome	4.26e-05	0.00882	CbGpPWpGaD
Vemurafenib—RAF1—IL-5 Signaling Pathway—IL2—acquired immunodeficiency syndrome	3.91e-05	0.00809	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	3.87e-05	0.008	CbGpPWpGaD
Vemurafenib—RAF1—GRB2 events in EGFR signaling—IL6—acquired immunodeficiency syndrome	3.85e-05	0.00796	CbGpPWpGaD
Vemurafenib—RAF1—SOS-mediated signalling—IL6—acquired immunodeficiency syndrome	3.85e-05	0.00796	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—IL2—acquired immunodeficiency syndrome	3.79e-05	0.00784	CbGpPWpGaD
Vemurafenib—RAF1—IL-2 Signaling Pathway—IL2—acquired immunodeficiency syndrome	3.76e-05	0.00778	CbGpPWpGaD
Vemurafenib—RAF1—Signalling to p38 via RIT and RIN—IL6—acquired immunodeficiency syndrome	3.71e-05	0.00767	CbGpPWpGaD
Vemurafenib—RAF1—SHC-mediated signalling—IL6—acquired immunodeficiency syndrome	3.71e-05	0.00767	CbGpPWpGaD
Vemurafenib—RAF1—SHC1 events in EGFR signaling—IL6—acquired immunodeficiency syndrome	3.71e-05	0.00767	CbGpPWpGaD
Vemurafenib—RAF1—ARMS-mediated activation—IL6—acquired immunodeficiency syndrome	3.58e-05	0.00741	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	3.54e-05	0.00732	CbGpPWpGaD
Vemurafenib—RAF1—IL2-mediated signaling events—IFNG—acquired immunodeficiency syndrome	3.46e-05	0.00716	CbGpPWpGaD
Vemurafenib—RAF1—Interleukin-2 signaling—IL2—acquired immunodeficiency syndrome	3.44e-05	0.00711	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	3.39e-05	0.00702	CbGpPWpGaD
Vemurafenib—RAF1—Frs2-mediated activation—IL6—acquired immunodeficiency syndrome	3.35e-05	0.00693	CbGpPWpGaD
Vemurafenib—RAF1—SHC-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	3.35e-05	0.00693	CbGpPWpGaD
Vemurafenib—RAF1—SHC-related events—IL6—acquired immunodeficiency syndrome	3.35e-05	0.00693	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—CSF2—acquired immunodeficiency syndrome	3.34e-05	0.00692	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	3.33e-05	0.00689	CbGpPWpGaD
Vemurafenib—RAF1—SHP2 signaling—IFNG—acquired immunodeficiency syndrome	3.27e-05	0.00677	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Leptin—IL6—acquired immunodeficiency syndrome	3.24e-05	0.00671	CbGpPWpGaD
Vemurafenib—RAF1—Prolonged ERK activation events—IL6—acquired immunodeficiency syndrome	3.15e-05	0.00651	CbGpPWpGaD
Vemurafenib—BRAF—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	3.08e-05	0.00637	CbGpPWpGaD
Vemurafenib—RAF1—IL2-mediated signaling events—IL2—acquired immunodeficiency syndrome	3.08e-05	0.00637	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—ACTG1—acquired immunodeficiency syndrome	3.06e-05	0.00633	CbGpPWpGaD
Vemurafenib—RAF1—SHC1 events in ERBB4 signaling—IL6—acquired immunodeficiency syndrome	3.06e-05	0.00633	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IFNG—acquired immunodeficiency syndrome	2.95e-05	0.0061	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	2.94e-05	0.00608	CbGpPWpGaD
Vemurafenib—RAF1—SHP2 signaling—IL2—acquired immunodeficiency syndrome	2.91e-05	0.00601	CbGpPWpGaD
Vemurafenib—BRAF—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	2.9e-05	0.00601	CbGpPWpGaD
Vemurafenib—RAF1—GRB2 events in ERBB2 signaling—IL6—acquired immunodeficiency syndrome	2.89e-05	0.00599	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.79e-05	0.00577	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—TNF—acquired immunodeficiency syndrome	2.76e-05	0.00571	CbGpPWpGaD
Vemurafenib—RAF1—SHC1 events in ERBB2 signaling—IL6—acquired immunodeficiency syndrome	2.75e-05	0.00569	CbGpPWpGaD
Vemurafenib—RAF1—TWEAK Signaling Pathway—TNF—acquired immunodeficiency syndrome	2.74e-05	0.00567	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL4—acquired immunodeficiency syndrome	2.63e-05	0.00543	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IL2—acquired immunodeficiency syndrome	2.62e-05	0.00542	CbGpPWpGaD
Vemurafenib—RAF1—VEGFR2 mediated cell proliferation—IL6—acquired immunodeficiency syndrome	2.62e-05	0.00542	CbGpPWpGaD
Vemurafenib—RAF1—Signalling to RAS—IL6—acquired immunodeficiency syndrome	2.62e-05	0.00542	CbGpPWpGaD
Vemurafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	2.55e-05	0.00527	CbGpPWpGaD
Vemurafenib—RAF1—Ceramide signaling pathway—TNF—acquired immunodeficiency syndrome	2.46e-05	0.00509	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	2.34e-05	0.00484	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	2.22e-05	0.0046	CbGpPWpGaD
Vemurafenib—RAF1—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	2.21e-05	0.00457	CbGpPWpGaD
Vemurafenib—RAF1—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	2.21e-05	0.00457	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	2.18e-05	0.00452	CbGpPWpGaD
Vemurafenib—RAF1—FCERI mediated MAPK activation—IL6—acquired immunodeficiency syndrome	2.17e-05	0.00449	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	2.17e-05	0.00448	CbGpPWpGaD
Vemurafenib—RAF1—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	2.13e-05	0.00441	CbGpPWpGaD
Vemurafenib—RAF1—FRS2-mediated cascade—IL6—acquired immunodeficiency syndrome	2.13e-05	0.00441	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	2.03e-05	0.00421	CbGpPWpGaD
Vemurafenib—BRAF—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.03e-05	0.0042	CbGpPWpGaD
Vemurafenib—RAF1—Interleukin-2 signaling—IL6—acquired immunodeficiency syndrome	2.02e-05	0.00418	CbGpPWpGaD
Vemurafenib—RAF1—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	2.01e-05	0.00416	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2e-05	0.00413	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IFNA1—acquired immunodeficiency syndrome	1.99e-05	0.00413	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	1.95e-05	0.00404	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	1.93e-05	0.00399	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—acquired immunodeficiency syndrome	1.91e-05	0.00395	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	1.89e-05	0.0039	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—IL2—acquired immunodeficiency syndrome	1.77e-05	0.00366	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CCNT1—acquired immunodeficiency syndrome	1.73e-05	0.00357	CbGpPWpGaD
Vemurafenib—RAF1—SHP2 signaling—IL6—acquired immunodeficiency syndrome	1.71e-05	0.00353	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	1.59e-05	0.00328	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MBL2—acquired immunodeficiency syndrome	1.58e-05	0.00328	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	1.57e-05	0.00326	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—CSF2—acquired immunodeficiency syndrome	1.56e-05	0.00323	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	1.54e-05	0.00318	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.51e-05	0.00313	CbGpPWpGaD
Vemurafenib—RAF1—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	1.5e-05	0.00311	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—acquired immunodeficiency syndrome	1.5e-05	0.00311	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	1.48e-05	0.00307	CbGpPWpGaD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—TNF—acquired immunodeficiency syndrome	1.46e-05	0.00303	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—TAT—acquired immunodeficiency syndrome	1.46e-05	0.00302	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	1.42e-05	0.00293	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL2—acquired immunodeficiency syndrome	1.41e-05	0.00292	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APOBEC3G—acquired immunodeficiency syndrome	1.41e-05	0.00291	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APOBEC3G—acquired immunodeficiency syndrome	1.39e-05	0.00288	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	1.38e-05	0.00286	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	1.32e-05	0.00272	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	1.31e-05	0.0027	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	1.28e-05	0.00266	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.28e-05	0.00265	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	1.26e-05	0.00261	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	1.26e-05	0.00261	CbGpPWpGaD
Vemurafenib—RAF1—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	1.26e-05	0.0026	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.24e-05	0.00257	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CCR2—acquired immunodeficiency syndrome	1.24e-05	0.00257	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.24e-05	0.00257	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	1.23e-05	0.00254	CbGpPWpGaD
Vemurafenib—RAF1—IRS-related events—IL6—acquired immunodeficiency syndrome	1.22e-05	0.00253	CbGpPWpGaD
Vemurafenib—RAF1—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	1.21e-05	0.00251	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.21e-05	0.0025	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.21e-05	0.0025	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	1.2e-05	0.00249	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CCNT1—acquired immunodeficiency syndrome	1.2e-05	0.00247	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CCNT1—acquired immunodeficiency syndrome	1.18e-05	0.00245	CbGpPWpGaD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	1.18e-05	0.00244	CbGpPWpGaD
Vemurafenib—RAF1—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	1.18e-05	0.00244	CbGpPWpGaD
Vemurafenib—RAF1—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	1.18e-05	0.00244	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ACTG1—acquired immunodeficiency syndrome	1.12e-05	0.00232	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	1.12e-05	0.00231	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.09e-05	0.00226	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.09e-05	0.00226	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	1.09e-05	0.00225	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	1.06e-05	0.0022	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	1.06e-05	0.00219	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	1.05e-05	0.00216	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	1.04e-05	0.00216	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—IL6—acquired immunodeficiency syndrome	1.04e-05	0.00215	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TNF—acquired immunodeficiency syndrome	1.03e-05	0.00213	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	1.02e-05	0.00211	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.0021	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.01e-05	0.00209	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	9.96e-06	0.00206	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	9.88e-06	0.00204	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	9.81e-06	0.00203	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—CSF2—acquired immunodeficiency syndrome	9.72e-06	0.00201	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	9.59e-06	0.00198	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	9.59e-06	0.00198	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	9.28e-06	0.00192	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MBL2—acquired immunodeficiency syndrome	9.22e-06	0.00191	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CXCR4—acquired immunodeficiency syndrome	9.07e-06	0.00188	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	9.04e-06	0.00187	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	8.95e-06	0.00185	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.75e-06	0.00181	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	8.5e-06	0.00176	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	8.42e-06	0.00174	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	8.4e-06	0.00174	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	8.39e-06	0.00174	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.37e-06	0.00173	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.37e-06	0.00173	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL6—acquired immunodeficiency syndrome	8.29e-06	0.00172	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	8.24e-06	0.00171	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	8.16e-06	0.00169	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	8.16e-06	0.00169	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	8.08e-06	0.00167	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	8.03e-06	0.00166	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TAT—acquired immunodeficiency syndrome	7.93e-06	0.00164	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.92e-06	0.00164	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	7.9e-06	0.00163	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.57e-06	0.00157	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	7.55e-06	0.00156	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	7.51e-06	0.00155	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.47e-06	0.00155	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	7.47e-06	0.00155	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.44e-06	0.00154	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.44e-06	0.00154	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—acquired immunodeficiency syndrome	7.43e-06	0.00154	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CCR2—acquired immunodeficiency syndrome	7.23e-06	0.0015	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	6.99e-06	0.00145	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	6.99e-06	0.00145	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—acquired immunodeficiency syndrome	6.99e-06	0.00145	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	6.93e-06	0.00143	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—acquired immunodeficiency syndrome	6.89e-06	0.00143	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	6.87e-06	0.00142	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	6.84e-06	0.00142	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.76e-06	0.0014	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AGPS—acquired immunodeficiency syndrome	6.74e-06	0.00139	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IFNA1—acquired immunodeficiency syndrome	6.68e-06	0.00138	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	6.58e-06	0.00136	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	6.54e-06	0.00135	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNA1—acquired immunodeficiency syndrome	6.51e-06	0.00135	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.35e-06	0.00131	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.35e-06	0.00131	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ALB—acquired immunodeficiency syndrome	6.33e-06	0.00131	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD79A—acquired immunodeficiency syndrome	6.32e-06	0.00131	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CXCR4—acquired immunodeficiency syndrome	6.28e-06	0.0013	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CXCR4—acquired immunodeficiency syndrome	6.22e-06	0.00129	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CCR5—acquired immunodeficiency syndrome	6.22e-06	0.00129	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	6.19e-06	0.00128	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	5.99e-06	0.00124	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.72e-06	0.00118	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.66e-06	0.00117	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.58e-06	0.00115	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	5.56e-06	0.00115	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	5.54e-06	0.00115	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.48e-06	0.00113	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.43e-06	0.00112	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	5.36e-06	0.00111	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—CSF2—acquired immunodeficiency syndrome	5.23e-06	0.00108	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.17e-06	0.00107	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40LG—acquired immunodeficiency syndrome	5.15e-06	0.00107	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2—acquired immunodeficiency syndrome	5.14e-06	0.00106	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.1e-06	0.00106	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—acquired immunodeficiency syndrome	5.1e-06	0.00105	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CSF2—acquired immunodeficiency syndrome	5.1e-06	0.00105	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD4—acquired immunodeficiency syndrome	5.03e-06	0.00104	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-B—acquired immunodeficiency syndrome	4.9e-06	0.00101	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	4.85e-06	0.001	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.83e-06	0.001	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	4.83e-06	0.000999	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.78e-06	0.00099	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	4.76e-06	0.000986	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.76e-06	0.000985	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	4.71e-06	0.000975	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.68e-06	0.000968	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.4e-06	0.00091	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.4e-06	0.00091	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.36e-06	0.000901	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—acquired immunodeficiency syndrome	4.31e-06	0.000892	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CCR5—acquired immunodeficiency syndrome	4.3e-06	0.00089	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	4.28e-06	0.000885	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CCR5—acquired immunodeficiency syndrome	4.27e-06	0.000883	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD4—acquired immunodeficiency syndrome	3.91e-06	0.000808	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.81e-06	0.000789	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.64e-06	0.000753	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.34e-06	0.000692	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.29e-06	0.000682	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.08e-06	0.000637	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—acquired immunodeficiency syndrome	3.03e-06	0.000627	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.01e-06	0.000624	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.95e-06	0.00061	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD4—acquired immunodeficiency syndrome	2.93e-06	0.000606	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—acquired immunodeficiency syndrome	2.76e-06	0.000572	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.72e-06	0.000562	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—acquired immunodeficiency syndrome	2.7e-06	0.000559	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—acquired immunodeficiency syndrome	2.69e-06	0.000557	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—acquired immunodeficiency syndrome	2.68e-06	0.000554	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—acquired immunodeficiency syndrome	2.55e-06	0.000527	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.52e-06	0.000521	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	2.24e-06	0.000463	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.17e-06	0.000449	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—acquired immunodeficiency syndrome	2.11e-06	0.000437	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.74e-06	0.00036	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.73e-06	0.000358	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—acquired immunodeficiency syndrome	1.58e-06	0.000328	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.48e-06	0.000306	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—acquired immunodeficiency syndrome	1.46e-06	0.000302	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—acquired immunodeficiency syndrome	1.45e-06	0.0003	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.14e-06	0.000236	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.02e-06	0.000212	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	9.67e-07	0.0002	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	7.46e-07	0.000154	CbGpPWpGaD
